Last reviewed · How we verify
APL-1202 in combination with Epirubicin
APL-1202 in combination with Epirubicin is a Small molecule drug developed by Jiangsu Yahong Meditech Co., Ltd aka Asieris. It is currently in Phase 3 development.
At a glance
| Generic name | APL-1202 in combination with Epirubicin |
|---|---|
| Sponsor | Jiangsu Yahong Meditech Co., Ltd aka Asieris |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APL-1202 in combination with Epirubicin CI brief — competitive landscape report
- APL-1202 in combination with Epirubicin updates RSS · CI watch RSS
- Jiangsu Yahong Meditech Co., Ltd aka Asieris portfolio CI
Frequently asked questions about APL-1202 in combination with Epirubicin
What is APL-1202 in combination with Epirubicin?
APL-1202 in combination with Epirubicin is a Small molecule drug developed by Jiangsu Yahong Meditech Co., Ltd aka Asieris.
Who makes APL-1202 in combination with Epirubicin?
APL-1202 in combination with Epirubicin is developed by Jiangsu Yahong Meditech Co., Ltd aka Asieris (see full Jiangsu Yahong Meditech Co., Ltd aka Asieris pipeline at /company/jiangsu-yahong-meditech-co-ltd-aka-asieris).
What development phase is APL-1202 in combination with Epirubicin in?
APL-1202 in combination with Epirubicin is in Phase 3.